2026-09-19T00:48:20Zhttps://dspace.mit.edu/server/oai/request

oai:dspace.mit.edu:1721.1/995732026-06-16T18:16:19Zcom_1721.1_7582com_1721.1_7581col_1721.1_131022

Susan Lindquist. Vincent, Benjamin Matteson Massachusetts Institute of Technology. Department of Biology. Massachusetts Institute of Technology. Department of Biology 2015-10-30T18:56:43Z 2015-10-30T18:56:43Z 2015 2015 http://hdl.handle.net/1721.1/99573 924823813 Thesis: Ph. D. in Microbiology, Massachusetts Institute of Technology, Department of Biology, 2015. Cataloged from PDF version of thesis. Includes bibliographical references The evolution of drug resistance in pathogenic microorganisms is typically viewed as an inevitable consequence of the selective pressures imposed by antimicrobial agents. However, although certain drugs rapidly lose efficacy in the clinic, others remain refractory to resistance. In my thesis, I tested the hypothesis that antifungal drug resistance is the outcome of diverse tradeoffs between the fitness benefits of resistance mutations and their costs upon the adaptive cellular factors that enable the evolution of new traits. I also pursued the discovery of novel small molecule inhibitors of fungal drug resistance to further delineate the cellular processes required to support this phenotype. First, I examined the mechanisms underlying the exceptionally low incidence of resistance to the polyene antifungal amphotericin B (AmB), a mainstay of antifungal therapy for over 50 years. Genome sequencing of AmB-resistant clinical isolates and mutants evolved in the laboratory revealed several loss-of-function mutations in ergosterol biosynthesis as causes of resistance. However, deeper phenotypic profiling of these mutants revealed that they all carried massive costs for the ability to tolerate environmental stressors and deploy virulence factors. I concluded that these costs sharply limit the emergence of resistance to AmB in the clinic. AmB is also extremely toxic to patients, a feature seen in many other resistance-refractory drugs. Collaborating with a synthetic chemistry team headed by Martin Burke (University of Illinois), we demonstrated that new, nontoxic AmB analogs with improved selectivity for the target (ergosterol) still retain the extremely valuable property of evading drug resistance. This finding countered the assumption that narrowing the target specificity of a drug would enable more routes to the emergence of resistance. Separately, I conducted a high-throughput screen for small molecule inhibitors of drug resistance in Candida. This screen identified a fungal-selective inhibitor of cytochrome bc1 of the electron transport chain. Collaborating with chemists (Jean- Baptiste Langlois and Stephen Buchwald) and structural modelers (Raja Srinivas and Bruce Tidor), we optimized the potency and fungal selectivity of this compound. Moreover, these studies provided insight into the role of mitochondrial respiration in fungal host adaptation, immune evasion, and virulence in an animal model. Finally, in the appendix I describe work in progress on the discovery and characterization of a compound that selectively kills Candida by targeting the mitochondrial phosphate transporter. Resistance to this agent sensitizes fungi to azoles and bears severe fitness costs, reminiscent of the case of AmB. by Benjamin Matteson Vincent. Ph.D. in Microbiology 207 pages eng Massachusetts Institute of Technology M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 Biology. Exploiting fitness trade-offs to prevent antifungal drug resistance Thesis application/pdf false Publication unknown unknown <Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="aad3f244-1cf6-4051-9c19-a454bfd58015"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>Exploiting fitness trade-offs to prevent antifungal drug resistance</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2015</PublicationDate> <Authors> <Author> <DisplayName>Vincent, Benjamin Matteson</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Massachusetts Institute of Technology</DisplayName> <OrgUnit /> </Publisher> </Publishers> <License>http://dspace.mit.edu/handle/1721.1/7582</License> <Keyword>Biology.</Keyword> <Abstract>The evolution of drug resistance in pathogenic microorganisms is typically viewed as an inevitable consequence of the selective pressures imposed by antimicrobial agents. However, although certain drugs rapidly lose efficacy in the clinic, others remain refractory to resistance. In my thesis, I tested the hypothesis that antifungal drug resistance is the outcome of diverse tradeoffs between the fitness benefits of resistance mutations and their costs upon the adaptive cellular factors that enable the evolution of new traits. I also pursued the discovery of novel small molecule inhibitors of fungal drug resistance to further delineate the cellular processes required to support this phenotype. First, I examined the mechanisms underlying the exceptionally low incidence of resistance to the polyene antifungal amphotericin B (AmB), a mainstay of antifungal therapy for over 50 years. Genome sequencing of AmB-resistant clinical isolates and mutants evolved in the laboratory revealed several loss-of-function mutations in ergosterol biosynthesis as causes of resistance. However, deeper phenotypic profiling of these mutants revealed that they all carried massive costs for the ability to tolerate environmental stressors and deploy virulence factors. I concluded that these costs sharply limit the emergence of resistance to AmB in the clinic. AmB is also extremely toxic to patients, a feature seen in many other resistance-refractory drugs. Collaborating with a synthetic chemistry team headed by Martin Burke (University of Illinois), we demonstrated that new, nontoxic AmB analogs with improved selectivity for the target (ergosterol) still retain the extremely valuable property of evading drug resistance. This finding countered the assumption that narrowing the target specificity of a drug would enable more routes to the emergence of resistance. Separately, I conducted a high-throughput screen for small molecule inhibitors of drug resistance in Candida. This screen identified a fungal-selective inhibitor of cytochrome bc1 of the electron transport chain. Collaborating with chemists (Jean- Baptiste Langlois and Stephen Buchwald) and structural modelers (Raja Srinivas and Bruce Tidor), we optimized the potency and fungal selectivity of this compound. Moreover, these studies provided insight into the role of mitochondrial respiration in fungal host adaptation, immune evasion, and virulence in an animal model. Finally, in the appendix I describe work in progress on the discovery and characterization of a compound that selectively kills Candida by targeting the mitochondrial phosphate transporter. Resistance to this agent sensitizes fungi to azoles and bears severe fitness costs, reminiscent of the case of AmB.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication>